Integrating Metabolomics and Network Pharmacology to Explore the Mechanism of Xiao-Yao-San in the Treatment of Inflammatory Response in CUMS Mice
Open Access
- 14 November 2023
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (11) , 1607
Abstract
Depression can trigger an inflammatory response that affects the immune system, leading to the development of other diseases related to inflammation. Xiao-Yao-San (XYS) is a commonly used formula in clinical practice for treating depression. However, it remains unclear whether XYS has a modulating effect on the inflammatory response associated with depression. The objective of this study was to examine the role and mechanism of XYS in regulating the anti-inflammatory response in depression. A chronic unpredictable mild stress (CUMS) mouse model was established to evaluate the antidepressant inflammatory effects of XYS. Metabolomic assays and network pharmacology were utilized to analyze the pathways and targets associated with XYS in its antidepressant inflammatory effects. In addition, molecular docking, immunohistochemistry, Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR), and Western Blot were performed to verify the expression of relevant core targets. The results showed that XYS significantly improved depressive behavior and attenuated the inflammatory response in CUMS mice. Metabolomic analysis revealed the reversible modulation of 21 differential metabolites by XYS in treating depression-related inflammation. Through the combination of liquid chromatography and network pharmacology, we identified seven active ingredients and seven key genes. Furthermore, integrating the predictions from network pharmacology and the findings from metabolomic analysis, Vascular Endothelial Growth Factor A (VEGFA) and Peroxisome Proliferator-Activated Receptor-γ (PPARG) were identified as the core targets. Molecular docking and related molecular experiments confirmed these results. The present study employed metabolomics and network pharmacology analyses to provide evidence that XYS has the ability to alleviate the inflammatory response in depression through the modulation of multiple metabolic pathways and targets.Keywords
Funding Information
- National Natural Science Foundation of China (82205229, 81673838, 2021A1515110798)
- Natural Science Foundation of Guangdong Province, China (82205229, 81673838, 2021A1515110798)
This publication has 53 references indexed in Scilit:
- From stress to inflammation and major depressive disorder: A social signal transduction theory of depression.Psychological Bulletin, 2014
- TCMSP: a database of systems pharmacology for drug discovery from herbal medicinesJournal of Cheminformatics, 2014
- PPAR-γ Agonism as a Modulator of Mood: Proof-of-Concept for Pioglitazone in Bipolar DepressionCNS Drugs, 2014
- Immune changes and neurotransmitters: Possible interactions in depression?Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014
- Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrationsBrain, Behavior, and Immunity, 2013
- Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug ActionAnnual Review of Pharmacology and Toxicology, 2012
- Increased peripheral NF-κB pathway activity in women with childhood abuse-related posttraumatic stress disorderBrain, Behavior, and Immunity, 2012
- Open Babel: An open chemical toolboxJournal of Cheminformatics, 2011
- A role for central nervous system PPAR-γ in the regulation of energy balanceNature Medicine, 2011
- Eating ourselves to death (and despair): The contribution of adiposity and inflammation to depressionProgress in Neurobiology, 2010